insider trader report

ACR / ACRUX LIMITED
Date Picked
30-09-2010
Price When Picked
$2.320
Company Overview
Inside Trader comments:

Here's a stock with 3 analysts giving it a STRONG BUY recommendation. The current price is $2.32 with 12mth price targets from various researchers from $3 to $4 per share.

The price has been rising over the last few months due to good revenue news and the expectation of a large dividend (maybe 50c). Even though the price has been rising, we are seeing buyer demand and smart money increasing.

Looks like a good medium to long term investment to us...

from their website:

Acrux is a dynamic Australian drug delivery business developing and commercialising a range of patient-preferred pharmaceutical products for global markets, using innovative, patented technology to administer drugs through the skin.

Fast drying, non-occlusive topical sprays or liquids provide an enhanced transdermal delivery platform with low or no skin irritation, superior cosmetic acceptability, and simple, accurate and flexible dosing. Acrux's product pipeline includes treatment of hormonal deficiencies, central nervous system disorders, contraception and dermatological conditions. The first product is being marketed in the USA by Acrux's licensee following approval by the US Food and Drug Administration (FDA).

Acrux has products in late stage development, follows a lower risk development path and is well funded. The six fundamentals of the business are:

- Faster, lower risk, lower cost development because products contain proven drugs

- Products designed to have strong competitive advantage ("patient-preferred and patent protected")

- Lead product successfully through FDA approval

- Products in clinical development for a range of therapeutic areas

- Track record of commercial deals

- Strong cash reserves